Get started
Work

XPO1 inhibition enhances the efficacy and durability of RAS-targeted therapy in preclinical models of KRASG12D mutant pancreatic ductal adenocarcinoma

Year: 2026
Type: article
DOI: 10.1016/j.canlet.2026.218804
Authors: Husain Yar Khan, Mohammed Najeeb Al Hallak, Amro Aboukameel, Sahar F. Bannoura, Md Hafiz Uddin, Adeeb A. Aboukameel, Fulya Koksalar Alkan, Ahmet B. Caglayan, Hilmi K. Alkan, Bin Bao, Hugo Jimenez, Allan M. Johansen, Callum McGrath, Grayson Barker, Khalil Choucair, Miguel Tobon, Eliza Beal, Steve Kim, Rafic Beydoun, Gregory Dyson, Yang Shi, Misako Nagasaka, Azeddine Atfi, Hasan Korkaya, Muhammad Wasif Saif, Philip A. Philip, Bassel El-Rayes, Herbert Chen, Anthony F. Shields, Ramzi M. Mohammad, Boris C. Pasche, Asfar S. Azmi
Institutions: Wayne State University, The Barbara Ann Karmanos Cancer Institute, University of California, Irvine, Henry Ford Health, Henry Ford Hospital, University of California San Diego, Moores Cancer Center, University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: closed
OpenAlex ID: W7204621263
FWCI:
Cites: 27
Cited by:
Related to: